CASP8 and prostate carcinoma: Our observation that the cleaved to pro-caspase-8 ratio increases in a dose dependent manner, reaching 2.8-fold elevation with rosuvastatin at 20 μg/mL in HT-29 cells, aligns with findings from Goc et al., who provided the first report demonstrating that simvastatin simultaneously modulates intrinsic and extrinsic pathways in prostate cancer cells [55].